January 3, 2018
Raises 2017 Guidance
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ:
LGND) announces that its partner HanAll Biopharma successfully out-licensed antibody
projects that were discovered by HanAll using Ligand’s OmniAb® antibody discovery
platform. The licensing events triggered $6 million of payments to Ligand. HanAll has had
access to the OmniAb platform since December 2014 and is developing multiple antibody
projects in the immunno-oncology and autoimmune areas using this platform. Under the
license agreements with HanAll, Ligand is eligible to receive milestones and royalties on
the successful development of antibodies and to share sub-license revenue on outlicensed
“These are excellent licensing transactions for HanAll and for Ligand, putting a clinicalstage
antibody into the hands of two partners to advance the development of the program
in markets around the world. The licenses illustrate the value and potential of the OmniAb
platform for delivering novel antibodies that succeed through the intense discovery
selection process,” said John Higgins, Chief Executive Officer of Ligand. “We are very
pleased with HanAll’s success in quickly moving one of its novel antibodies into human
trials in 2017 and in subsequently securing two license agreements for the antibody.
Ligand has a best-in-class antibody discovery technology with its OmniAb platform offering
three distinct species for drug discovery. Since acquiring the technology less than two
years ago, Ligand has expanded its portfolio of OmniAb partners and has secured
substantial partnering payments as the programs advance.”
Including these payments, Ligand now anticipates total revenue for full year 2017 to be
approximately $140 million with adjusted EPS to be between $3.13 and $3.16. Previous
guidance was for revenue to be between $134 and $136 million and for adjusted earnings
per share to be between $2.95 and $3.00.
OmniAb is a three-species transgenic-animal platform consisting of four different
technologies used for producing mono- and bispecific human therapeutic antibodies.
OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It
has a complete immune system with a diverse antibody repertoire and generates
antibodies with human idiotypes as effectively as wild-type animals make rat antibodies.
OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope
coverage. OmniFlic® is an engineered rat with a fixed light chain for development of
bispecific, fully human antibodies. OmniChicken™ is the industry’s first human monoclonal
antibody technology based on chickens. The four technologies use patented technology,
have broad freedom to operate and deliver fully human antibodies with high affinity,
specificity, expression, solubility and stability.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies
that help pharmaceutical companies discover and develop medicines. Our business model
creates value for stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an efficient and low
corporate cost structure. Our goal is to offer investors an opportunity to participate in the
promise of the biotech industry in a profitable, diversified and lower-risk business than a
typical biotech company. Our business model is based on doing what we do best: drug
discovery, early-stage drug development, product reformulation and partnering. We
partner with other pharmaceutical companies to leverage what they do best (late-stage
development, regulatory management and commercialization) to ultimately generate our
revenue. Ligand’s Captisol® platform technology is a patent-protected, chemically modified
cyclodextrin with a structure designed to optimize the solubility and stability of drugs.
OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully
human mono-and bispecific therapeutic antibodies. Ligand has established multiple
alliances, licenses and other business relationships with the world’s leading
pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead,
Janssen, Baxter International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
This news release contains forward-looking statements by Ligand that involve risks and
uncertainties and reflect Ligand’s judgment as of the date of this release. The failure to
meet expectations with respect to any of the foregoing matters may reduce Ligand’s stock
price. Additional information concerning these and other important risk factors affecting
Ligand can be found in Ligand’s prior press releases available at www.ligand.com as well
as in Ligand’s public periodic filings with the Securities and Exchange Commission,
available at www.sec.gov. Ligand disclaims any intent or obligation to update these
forward-looking statements beyond the date of this press release, except as required by
law. This caution is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
View source version on businesswire.com:
Ligand Pharmaceuticals Incorporated
Todd Pettingill, (858) 550-7893
LHA Investor Relations
Bruce Voss, (310) 691-7100
Source: Ligand Pharmaceuticals